How mesenchymal cancer cells undergo mesenchymal transition toepithelial in distant sites from the primary Rtumor And finally become micromEtastatic. We micrometastases in bone marrow of patients with breast cancer and found that the detection of micrometastases of carcinoma cells with distant metastasis-free survival rate is low, free local recurrence-free survival and overall VX-222 survival was associated. Despite the high rates of adjuvant systemic therapy and breast irradiation in this series remains carcinoma cells spread a prognostic factor for treatment resistance or remote spread of cancer cells in the bone marrow of patients positive. In addition, we discovered micrometastatic carcinoma cells in patients with T1 tumors, suggesting that the diffusion occurs much tt w During tumor progression is generally recognized. Thus should bone marrow micrometastases to be a useful prognostic indicator of relapse, and an excellent surrogate marker of the patient’s response to treatment. The as mesenchymal stemness cell carcinoma confers protection against cell death, the immune response and, more importantly, Best RESISTANCE escape to conventional therapies and targeted.
Current strategies are based on the concept of EMT tze new therapeutic Ans, The t with the plasticity Cancer cells st Develop Ren. Our laboratory has developed a high content of the screen for high-throughput EMT. SU11274 Various combinations of drugs were found to selectively inhibit EMT. This strategy can be used to st with tumor progression Acids, in particular in breast cancers that have developed resistance to herk Mmlichen therapies. DNA methylation and histone modifications cations r Important in normal breast development and breast cancer diff erentiation. Silen lacing epigenetic mediation of tumor suppressor genes and microRNAs is a feature of human breast tumors. CpG hypermethylation batch begins as a biomarker of disease, such as hypermethylation of the BRCA1 gene as Pr Predictor response to PARP inhibitors. More importantly, histone methylation and DNA is both modifi cations new targets for drugs to come.
The risk of breast cancer in women, the syndrome of insulin resistance, such as obesity, central obesity, high endogenous insulin, diabetes clinic, and lack of exercise leads risen. There is a lot of evidence that overweight ects connected with an increase of 25-50% compared to the risk of breast cancer recurrence or death, with negative eff appear to be independent Ngig of hormone receptor status. overweight, especially if it is of central importance, is strongly associated with insulin resistance in healthy subjects and patients with breast cancer. Several studies have shown that increased, the increase in insulin and / or C-peptide levels, both of which are associated with insulin resistance with a FITTINGS risk of recurrence and mortality associated with breast cancer at an early stage, even in the absence of diabetes. The risk is two to three times in h Ago as the insulin levels in the h Obtains highest quartile Ht. The data from our group show that these verb Nde prognostic insulin are the most in the fi rst 5 years after diagnosis pronounced Gt R Insulin in the results of breast cancer is biologically plausible, because the overexpression of insulin receptors, the h Common form fetal receptor, the majority of human breast cancer.